The
Company reported net losses for the three months ended March 31, 2026 and 2025. The following potentially dilutive securities were excluded
from the computation of diluted loss per share during the 2026 and 2025 periods of net loss, as their effect would have been anti-dilutive:
Schedule of Earnings Per Share Anti-diluted
| | |
2026 | | |
2025 | |
| | |
As of March 31, | |
| | |
2026 | | |
2025 | |
| Warrants to purchase common stock | |
| 1,411,566 | | |
| 712,500 | |
| Options | |
| 2,632,695 | | |
| 2,729,568 | |
| Non-vested restricted stock unit awards | |
| 2,681,835 | | |
| - | |
| Non-vested restricted common stock | |
| 3,069,272 | | |
| 1,312,301 | |
| Shares issuable upon conversion of convertible notes | |
| 2,107,757 | | |
| - | |
| Total | |
| 11,903,125 | | |
| 4,754,369 | |
| Anti-dilutive securities | |
| 11,903,125 | | |
| 4,754,369 | |
|